Press release | 28th April 2014
Neural ID and IDBS to Launch Customer-Focused Collaboration at Bio-IT World
Neural ID Enables IDBS BioBook Users to Audit and Analyze Biosignal Content Directly From Reports
San Francisco, CA, Boston, US & London, UK, – Neural ID, the provider of the only collaborative biosignal analytics platform spanning the pharmaceutical lifecycle, teams up with IDBS for customer-focused collaboration. The collaborative offering delivers a fully integrated solution which is being launched during Bio-IT World Conference & Expo, April 29-May 1 in Boston. It combines BioBook, IDBS’ electronic laboratory notebook for life sciences and Neural ID’s flagship product IWS which provides users with automated data analysis and data reporting.
For the first time BioBook users will have the ability to achieve full traceability and drill down capacity of the study lifecycle. This includes summary reports through study design and analyzed data, down to processed instrumentation biosignals. The summary data reported into BioBook from IWS will be fully searchable, a unique capability. Users of IWS will be able to generate deep analytic value across cardio safety assessments from discovery all the way through clinical applications and support GxP regulated environments.
As part of the collaboration, the two companies will present on how new approaches in machine learning and scalable biosignal analytics will extend expert knowledge and improve safety assessment during Bio-IT World on April 30th at 12 Noon ET.
“Researchers are keen to reduce study cycle times and accelerate decision making around the safety and efficacy of new products. We recognize the need for a consistent and reproducible way to automate waveform analysis throughout the drug discovery and development lifecycle,” said Scott Weiss, Director, Product Strategy, IDBS. “Our collaboration with Neural ID addresses this critical need. The integration will eliminate manual data import, reducing transcription errors. It also provides improved user productivity with automated write-up and reporting.”
“The IDBS and Neural ID collaboration has already resulted in one Top-20 pharmaceutical company integrating BioBook with IWS. Customers are realizing IWS expands their analysis capability to make better decisions, faster. We look forward to working with the IDBS team to help more of their customers accelerate bringing products to market.” said Timothy Carruthers, CEO, Neural ID.
For more information on Neural ID and IDBS, please visit booths 223 and 141-143 respectively at Bio-IT World.
About Neural ID
Neural ID provides the only collaborative biosignal analytics platform spanning the pharmaceutical lifecycle. From the discovery process through clinical and health information, Neural ID deliver s scalable enterprise solution addressing the industry’s productivity crisis. Our flagship product, Intelligent Waveform Solution (IWS) delivers expert-driven machine learning, massive data reduction and an interoperable data format to help customers make better decisions faster, leading to increased product revenues and reduced development costs. Neural ID, based in Redwood City, CA, launched IWS in 2013. Further information is available at www.neuralid.com
IDBS is a leading global provider of advanced software for research and development (R&D) organizations to securely capture, manage, share and exploit structured and unstructured data. Our technology and domain expertise enable users to link data to data, data to people and people to people to drive innovation, achieve faster time to market and improve margins. Our diverse customer list includes R&D driven international companies in pharmaceuticals, biotechnology, agricultural sciences, chemicals, consumer goods, energy, engineering, food and beverage, and healthcare.
Founded in 1989, IDBS is headquartered in the United Kingdom with offices across Europe, Asia and the United States. IDBS remains a privately held company employing over 350 staff across the world and serving over 50,000 researchers in 25 countries – including over 75% of the top twenty pharmaceutical companies.
Further information can be found at www.idbs.com or follow us on Twitter @IDBSsoftware.